• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Arcadia Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    4/3/25 4:15:24 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $RKDA alert in real time by email
    8-K
    0001469443false00014694432025-03-282025-03-28

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 28, 2025

     

     

    Arcadia Biosciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-37383

    81-0571538

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    5950 Sherry Lane

    Suite 215

     

    Dallas, Texas

     

    75225

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 214 974-8921

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common

     

    RKDA

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 1.01 Entry into a Material Definitive Agreement.

    On March 28, 2025, Arcadia Biosciences, Inc. (the "Company") entered into an agreement (the "Agreement") with a third party pursuant to which (i) the third party agreed to transfer to the Company all rights and materials relating to certain intellectual property rights and traits that were included in licenses previously granted by the Company to the third party, returning those rights to the Company; (ii) the third party agreed to pay a total of $750,000 to the Company; (iii) the Company agreed to transfer to the third party all of the Company's reduced gluten granted patents and pending applications and oxidative stability granted patents and pending applications, and related materials and documents; and (iv) the Company and the third party agreed to amend a previous agreement between the parties to eliminate any obligation to pay the Company future product royalties under the agreement.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

    Description

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    ARCADIA BIOSCIENCES, INC.

     

     

     

     

    Date:

    April 3, 2025

    By:

    /s/ MARK KAWAKAMI

     

     

     

    Mark Kawakami, Chief Financial Officer

     


    Get the next $RKDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RKDA

    DatePrice TargetRatingAnalyst
    1/3/2022$7.00 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RKDA
    SEC Filings

    See more
    • Arcadia Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)

      5/16/25 5:21:37 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 10-Q filed by Arcadia Biosciences Inc.

      10-Q - Arcadia Biosciences, Inc. (0001469443) (Filer)

      5/8/25 8:07:59 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 425 filed by Arcadia Biosciences Inc.

      425 - Arcadia Biosciences, Inc. (0001469443) (Subject)

      5/8/25 8:06:33 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

      -- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has

      5/8/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

      DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2025 on May 8, 2025. The company has scheduled a conference call for 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the following options: An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.To join the live call, please register

      4/29/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

      -- Year-over-year revenues grew 56% in Q4 and 13% for full year -- -- Zola® year-over-year revenues increased 124% in Q4 and 46% for full year -- -- Company plans business combination with Roosevelt Resources, Inc. -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. "We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets," said T.J. Schaefer, president and CEO. "Our focus on Zola® coconut water led to 80 percent revenue growth f

      3/20/25 4:05:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcadia Biosciences (RKDA) Announces Leadership Transition

      -- CEO Stan Jacot replaced by CFO Thomas J. Schaefer -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that CEO Stan Jacot has left the company and been replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer was previously Arcadia's chief financial officer and will be replaced in that role by Mark Kawakami, Arcadia's current vice president of finance. "On behalf of Arcadia, I would like to thank Stan for his many contributions to the company," said Board of Directors Chairman Kevin Comcowich. "Under his leadership, Arcadia expanded the GoodWheat brand into three categories, sold the brand to

      7/9/24 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO

      DAVIS, Calif., Dec. 20, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO. As previously announced on September 7, 2021, the board of directors launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector.

      12/20/21 10:55:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Appoints Seasoned CPG Sales Executive Brian Schaffer to Senior Vice President of Sales

      DAVIS, Calif., Nov. 22, 2021 /PRNewswire/ --  Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has named Brian Schaffer as senior vice president of sales, as the company continues to expand its consumer goods platforms. A seasoned sales and general management executive with deep CPG experience, Schaffer has a proven track record of building and leading world class sales organizations. He is tasked with driving the retail launch of Arcadia's GoodWheat brand, a company priority in 2022 as it w

      11/22/21 8:00:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Financials

    Live finance-specific insights

    See more

    $RKDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RKDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RKDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $RKDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

      -- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has

      5/8/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

      DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2025 on May 8, 2025. The company has scheduled a conference call for 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the following options: An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.To join the live call, please register

      4/29/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

      -- Year-over-year revenues grew 56% in Q4 and 13% for full year -- -- Zola® year-over-year revenues increased 124% in Q4 and 46% for full year -- -- Company plans business combination with Roosevelt Resources, Inc. -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. "We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets," said T.J. Schaefer, president and CEO. "Our focus on Zola® coconut water led to 80 percent revenue growth f

      3/20/25 4:05:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 4 filed by Chief Financial Officer Kawakami Mark

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      5/12/25 8:56:01 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 4 filed by Chief Executive Officer Schaefer Thomas J.

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      5/12/25 8:48:31 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:34:41 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:34:41 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Executive Officer Schaefer Thomas J. bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 33% to 2,819 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:24:18 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Financial Officer Kawakami Mark bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 55% to 1,981 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      8/20/24 8:11:11 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously

      1/3/22 6:06:17 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously

      6/1/21 6:50:30 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Lake Street initiated coverage on Arcadia Biosciences with a new price target

      Lake Street initiated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $4.50

      5/11/21 12:00:10 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form SC 13G/A filed by Arcadia Biosciences Inc. (Amendment)

      SC 13G/A - Arcadia Biosciences, Inc. (0001469443) (Subject)

      2/14/24 2:55:48 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form SC 13G filed by Arcadia Biosciences Inc.

      SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

      1/3/24 12:26:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form SC 13G filed by Arcadia Biosciences Inc.

      SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

      2/14/23 1:22:05 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples